Sign in to continue:

Saturday, March 7th, 2026

C-MER Medical Holdings Limited Announces Positive Profit Turnaround for FY2025 with Expected HK$90-110 Million Attributable Profit 1

Important Shareholder Information

  • Potential Share Price Impact: The expected return to profitability, combined with revenue growth and improved operational efficiency, is likely to be viewed positively by investors. The absence of impairment losses this year is a material change from FY2024 and could significantly impact market sentiment and share value.
  • Ongoing Review: Shareholders and prospective investors are advised to exercise caution when dealing in the shares of the Company, as the figures are provisional and subject to change pending audit.
  • Management Team: The Board is led by Chairman and independent non-executive Director Dr. Rex Auyeung Pak-kuen, Vice Chairman and CEO Ms. Li Xiaoting, Executive Director Dr. Lee Yau Wing Vincent, and five other independent non-executive Directors. This diverse and experienced board provides oversight and governance for the Group.
  • Upcoming Results Announcement: The full audited annual results for FY2025 will be published by the end of March 2026. Investors should review these results for comprehensive information before making investment decisions.

Additional Details for Investors

  • The expected profit range (HK\$90.0 million to HK\$110.0 million) marks a strong recovery from last year’s loss, indicating a return to financial health and potentially renewed investor confidence.
  • Revenue growth, though modest, combined with strategic closure of non-performing units, signals proactive management and commitment to profitability.
  • The elimination of impairment losses is a key driver for the turnaround, highlighting effective asset management and risk mitigation.
  • Shareholders should stay updated with the upcoming audited financial results, as adjustments may occur during the audit process.

Disclaimer

The information provided in this article is based on a preliminary announcement by C-MER Medical Holdings Limited and may be subject to change following the completion of the audit. Investors and shareholders are strongly advised to await the official audited results and consider all available information before making any investment decisions. This article does not constitute investment advice.

View C-MER MEDICAL Historical chart here



ENN Natural Gas Co., Ltd. Share Dealings Disclosure by Morgan Stanley & Co. International plc – 2026 Scheme of Arrangement 1

Morgan Stanley Securities Dealings in ENN Natural Gas Co., Ltd. – Investor Report Morgan Stanley Securities Dealings in ENN Natural Gas Co., Ltd. – Detailed Report for Investors Key Highlights Date of Disclosure: 2...

China Railway Construction Corporation Limited 2026 First Extraordinary General Meeting Notice and Director Election Details

China Railway Construction Corporation Limited Announces 2026 First Extraordinary General Meeting China Railway Construction Corporation Limited to Hold 2026 First Extraordinary General Meeting Key Highlights for Investors Date and Venue: The 2026 first extraordinary...

Apollo Future Mobility Group Forms Joint Venture for EV Sales and Manufacturing in Ningbo, China

Apollo Future Mobility Group Announces Formation of Major EV Joint Venture Apollo Future Mobility Group Announces Formation of Major EV Joint Venture Key Highlights of the Discloseable Transaction Joint Venture Formation: Apollo Future Mobility...

   Ad